P886: EFFICACY, SURVIVAL AND SAFETY OF SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SUBGROUP DATA FROM THE BOSTON TRIAL
Maria-Victoria Mateos,
Monika Engelhardt,
Xavier Leleu,
Mercedes Gironella Mesa,
Holger W. Auner,
Michele Cavo,
Meletios A. Dimopoulos,
Martina Bianco,
Giovanni Marino Merlo,
Charles la Porte,
Philippe Moreau
Affiliations
Maria-Victoria Mateos
1 Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain
Monika Engelhardt
2 Interdisciplinary Cancer Center, University of Freiburg, Freiburg, Germany
Xavier Leleu
3 Hôpital La Mileterie, Centre Hospitalier Universitaire, Poitiers, France
Mercedes Gironella Mesa
4 University Hospital Vall d’Hebron, Barcelona, Spain
Holger W. Auner
5 The Langmuir Myeloma Centre, Imperial College London, London, United Kingdom
Michele Cavo
6 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Haematology, Bologna University School of Medicine, Bologna, Italy
Meletios A. Dimopoulos
7 National and Kapodistrian University of Athens School of Medicine, Athens, Greece
Martina Bianco
8 Stemline Therapeutics/Menarini Group, New York City, United States
Giovanni Marino Merlo
8 Stemline Therapeutics/Menarini Group, New York City, United States
Charles la Porte
8 Stemline Therapeutics/Menarini Group, New York City, United States
